The Latin America, Middle East and Africa Plasma Protein Therapeutics Market would witness market growth of 11.3% CAGR during the forecast period (2023-2029).
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune blood condition that results in low platelet counts, which are crucial for blood coagulation. Similarly, Kawasaki Syndrome is the primary cause of cardiac disease in children under five. Failure to diagnose it could lead to heart damage and death. In all of these disorders, plasma protein therapeutics can treat patients, enabling them to live fairly regular lives.
Rising aging and anemic populations also increase the demand for plasma protein therapeutics. The rise in the senior population results from greater life expectancy brought on by technological advancements, advantageous reimbursement policies, as well as improved standards of living. The greatest risk factor for the emergence of cardiovascular, neurological, and other chronic disorders is thought to be aging. Furthermore, the market for plasma protein therapeutics is expanding significantly due to a rise in the adoption of strategies by prominent industry participants. These tactics are intended to help companies increase their market share and product offerings, expanding the market.
The public healthcare system in Brazil offers free comprehensive care to those with hemophilia, as the nation has the third largest proportion of people suffering from hemophilia. A well-coordinated nationwide program must include aspects such as maintaining an up-to-date patient registry, recording the frequency of problems, and evaluating resource utilization efficiency. In 2013, 9,122 patients with hemophilia A were registered in Brazil, of whom 36.1% had a severe condition, according to clinical, sociodemographic, and laboratory data gathered by the Brazilian computerized system on coagulopathies. Hence, the demand for plasma protein therapeutics will increase significantly in the region in the coming years.
The Brazil market dominated the LAMEA Plasma Protein Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $765.3 Million by 2029. The Argentina market is experiencing a CAGR of 11.9% during (2023 - 2029). Additionally, The UAE market would display a CAGR of 11% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, and Others. Based on Product Type, the market is segmented into Immunoglobulin, Albumin, Plasma derived factor VIII, and Others. Based on Application, the market is segmented into Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Plasma Protein Therapeutics Market is Projected to reach USD 39.1 Billion by 2029, at a CAGR of 5.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Abeona Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Grifols, S.A., Baxter International, Inc., Kedrion S.p.A, Octapharma AG, CSL Limited (CSL Behring), Taibang Biological Group Co., Ltd and ADMA Biologics, Inc.
By End User
By Product Type
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 